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A B S T R A C T
Hypothyroidism is a common endocrine disorder that predominantly occurs in females. It is associated with an
increased risk of cardiovascular diseases (CVD), but the molecular mechanism is not known. Disturbance in lipid
metabolism, the regulation of oxidative stress, and inﬂammation characterize the progression of subclinical
hypothyroidism. The initiation and progression of endothelial dysfunction also exhibit these changes, which is
the initial step in developing CVD. Animal and human studies highlight the critical role of nitric oxide (NO) as a
reliable biomarker for cardiovascular risk in subclinical and clinical hypothyroidism. In this review, we sum-
marize the recent literature ﬁndings associated with NO production by the thyroid hormones in both physio-
logical and pathophysiological conditions. We also discuss the levothyroxine treatment eﬀect on serum NO levels
in hypothyroid patients.
1. Introduction
Atherosclerosis is among the signiﬁcant causes of overall morbidity
and mortality in the general population. Overall, the risk factors for
atherosclerosis development include metabolic syndrome (MetS) com-
ponents (insulin resistance, dyslipidemia, central obesity, hyperten-
sion), smoking, and sedentary lifestyle [1–3]. Despite the confusing
conclusions of some studies, both MetS and atherosclerosis are strongly
associated with hypothyroidism [4–7]. Thyroid hormones facilitate the
normal functioning of cardiovascular physiology, while clinical or
subclinical hypothyroidism leads to alterations in hemodynamics, ves-
sels and cardiac morphology and physiology, hypertension, and ac-
celerated atherosclerosis [8–12]. Despite numerous evidence links un-
balanced thyroid hormones action with cardiovascular diseases (CVD),
the molecular mechanisms of these pathologies remain poorly explored.
However, literature evidence suggests that endothelial dysfunction (ED)
and altered nitric oxide (NO) production are among the main factors
causing these disorders.
The physiological production of NO has beneﬁcial eﬀects on the
cardiovascular system (CVS), maintaining vascular tone, controlling
https://doi.org/10.1016/j.biopha.2020.109881
Received 25 October 2019; Received in revised form 25 December 2019; Accepted 6 January 2020
Abbreviation: ADMA, asymmetrical dimethylarginine; Akt, protein kinase B; AMPK, adenosine monophosphate-activated protein kinase; CAMK2B, calmodulin-
dependent protein kinase Iiβ; CVD, cardiovascular diseases; sGC, soluble guanylate cyclase; cGMP, cyclic guanosine monophosphate; CRP, C-reactive protein; CVS,
cardiovascular system; ED, endothelial dysfunction; eNOS, endothelial nitric oxide synthase; GTP, guanosine triphosphate; HDL, high density lipoprotein; IL, 6-
interleukin 6; iNOS, inducible nitric oxide synthase; I, integrin receptor; L, Arg-L-Arginine; LDL, low density lipoprotein; LT4, levothyroxine; MAPK, mitogen-
activated protein kinase; MetS, metabolic syndrome; NO, nitric oxide; NOS, nitric oxide synthase; nNOS, neuronal nitric oxide synthase; PI3K, phosphatidylinositol 3-
kinase; PKA, protein kinase A; PKG, protein kinase G; T3, triiodothyronine; T4, thyroxine; THRα, nuclear receptors alpha; TSH, thyroid-stimulating hormone; TNF, α-
tumor necrosis factor-α; VASP, vasodilator-stimulated phosphoprotein; VSMC, vascular smooth muscle cells
⁎ Corresponding author at: Vinca Institute of Nuclear Sciences, University of Belgrade, Laboratory for Radiobiology and Molecular Genetics, P.O. Box 522, 11000
Belgrade, Serbia.
E-mail addresses: zorangluvic@yahoo.com (Z.M. Gluvic), obradovicmilan@hotmail.com (M.M. Obradovic), emma_crash@yahoo.com (E.M. Sudar-Milovanovic),
sonjazaﬁrovic@hotmail.com (S.S. Zaﬁrovic), radak@ikvbd.com (D.J. Radak), magbubah.essack@kaust.edu.sa (M.M. Essack),
vladimir.bajic@kaust.edu.sa (V.B. Bajic), takashi.gojobori@kaust.edu.sa (G. Takashi), isenovic@yahoo.com (E.R. Isenovic).
Biomedicine & Pharmacotherapy 124 (2020) 109881
0753-3322/ © 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
leukocyte adhesion, and platelet aggregation. Also, NO provide anti-
inﬂammatory and antioxidant eﬀects [13–16]. Moreover, NO is an
endothelium-derived relaxing factor, which is critical for CVS home-
ostasis [17–19]. Reduced bioactivity and bioavailability of NO in the
vasculature is the major contributor and a marker of ED [7,20,21].
Various hormones, including thyroid hormones [20,22–25], regulate
the activity of nitric oxide synthase (NOS) and NO production, while
altered NO level is associated with thyroid dysfunction [8,26].
Understanding the regulation of NO production by thyroid hor-
mones and thyroid-stimulating hormone (TSH) may provide new and
useful insight of how ED links to thyroid function alterations and dis-
eases. Thus NO may be a potential biochemical marker of thyroid dis-
eases.
In this review, we summarize the recent literature related to NO
production and its role in hypothyroidism (Table 1) and discuss the
eﬀects of levothyroxine (LT4) treatment on NO levels in the serum of
hypothyroid patients.
2. Nitric oxide – mechanism of action and function
Nitric oxide is a lipophilic molecule involved in various physiolo-
gical and pathophysiological processes [20,27], and also the ﬁrst gas-
eous molecule described as a mediator in signaling pathways [28]. It is
an intracellular molecule with a very short biological half-life of only a
few seconds or even less [29], but despite that, NO can produce remote
or long-lasting and prolonged eﬀects [30] via generation of diﬀerent S-
nitrosothiols (SNO) which are carriers of NO [31]. S-nitrosylation of the
reactive cysteine thiol group on diﬀerent proteins forms SNO, and then
the nitrosyl moiety is transferred between interacting proteins as a
means of transporting the NO signal to a distant location by transni-
trosylation [32]. Throughout the years it was thought that the NO
molecule only diﬀuses freely across cell membrane phospholipid bi-
layer, but the discovery of new membrane transport functions exerted
by membrane channel proteins such as aquaporin-1 (AQP-1) [33–35]
and connexins [36] challenges this concept. Disturbance of NO trans-
port/conduction through these channels suggests a possible alternate
origin of the diseases currently explained by insuﬃcient NO bioavail-
ability [33,36–38].
NO is a molecule generated and/or present in many diﬀerent cell
types throughout the body [39], such as vascular smooth muscle cells
(VSMC), endothelial cells, central and peripheral neurons, epithelial
cells of various organs, pancreatic islet cells, kidney macula densa cells,
macrophages, etc. [40]. It is known that NO plays an essential role in
various physiological processes such as neuronal signaling, synaptic
plasticity, immune and inﬂammatory response, ion channels regulation,
phagocytic defense mechanism, penile erection, as well as cardiovas-
cular homeostasis and atherogenesis [41]. Nevertheless, NO is gener-
ated primarily in blood vessel endothelial cells, which are the primary
source of NO production in CVS under physiological conditions [42].
NO interaction with diﬀerent signaling molecules initiates eﬀects, while
its interaction with free radicals leads to multiple biological reactions
[43,44], thereby inﬂuencing diﬀerent metabolic and membrane trans-
port processes [37,38].
NOS enzymes synthesize NO by converting the amino acid L-
Arginine (L-Arg) and oxygen into NO and citrulline [45–47]. It has been
shown that the availability of L-Arg is one of the limiting factors for NO
synthesis in the vascular adventitia of rats with sepsis [48]. NOS is a
family of enzymes consisting of 3 isoforms, including neuronal NOS
(nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) [49]. The
biological eﬀect of NO on the CVS depends on the NOS isoform that is
activated. Constitutively expressed forms in mammalian cells are nNOS
and eNOS, while NO produced by iNOS has proinﬂammatory and de-
fensive eﬀects [49,50]. eNOS is the most common isozyme in the
healthy vascular system, and it is activated by phosphorylation at dif-
ferent regulatory sites via protein kinases [51]. Stimulatory phosphor-
ylation of eNOS at Serine1177 usually occurs via the activity of protein
kinase A (PKA), protein kinase B (Akt), adenosine monophosphate-ac-
tivated protein kinase (AMPK), or calmodulin-dependent protein kinase
IIβ (CAMK2B), while the inhibitory phosphorylation of eNOS at
threonine495 occurs via Rho-kinase and protein kinase C [52]. Another
enzyme, arginase, also uses the substrate L-Arg and plays a critical role
in the NO synthesis regulation by reducing the L-Arg availability for NO
production [53].
In VSMC, cardiac myocytes, and platelets, NO activates soluble
guanylate cyclase (sGC) and increases the level of cyclic guanosine
monophosphate (cGMP), which activates protein kinase G (PKG) and its
subsequent signaling pathway, which leads to cell relaxation and con-
sequently blood vessels dilatation [54,55]. Increased cGMP level also
leads to anti-inﬂammatory properties as it inhibits leukocytes adhesion
to the endothelium and platelet aggregation [56]. Furthermore, when
NO is overproduced, NO could also exert its eﬀects through sGC-in-
dependent mechanisms [54,57]. Production of large amounts of NO and
its reaction with superoxide anion, form the toxic compound perox-
ynitrite, that may induce nitrosative stress [58,59]. Increased ni-
trosative stress leads to nitration and S-nitrosylation of macro-
molecules, including lipids, proteins, and DNA that may cause tissue
damage and dysfunction [60]. On the other hand, under physiological
conditions, in the presence of a low level of reactive oxygen species, NO
protects cells from further oxidative modiﬁcation also by protein S-ni-
trosylation [31,32,61–64], which is nowadays an emerging paradigm of
redox signaling [32]. Proper regulation of S-nitrosylation is vital for
normal physiology, while its dysregulation leads to pathological con-
ditions [32,65].
An imbalance between endothelial vasodilators (predominantly NO)
and vasoconstrictors leads to ED, which is a part of numerous cardio-
vascular and other systemic diseases. ED is an early event in the
atherosclerosis process [66–68] characterized by a decrease in NO
synthesis, release, and activity [69–71]. Decreased bioavailability of
NO is one of several probable causes of ED [72], and it features in
hyperthyroid [73], and both subclinical [74] and clinical hypothyroid
Table 1
Hypothyroidism-related complications and altered NO production.
Study group Pathophysiological process NO-related eﬀects Reference
Patients with hypothyroidism Atherosclerosis ↓Endothelial NO production [120]
Dyslipidemia ↓NO [74]
ED and Hyperlipidemia ↓NO [9]
ED and Hyperlipidemia ↓eNOS expression [112]
ED and Chronic inﬂammation ↓Flow-mediated dilation [122]
ED and Chronic inﬂammation ↓NO availability [129]
Hypothyroid rats ED and Heart failure ↓Atrial NOS activity [138]
Cognitive dysfunction and Brain tissue oxidative damage ↑NO [140,141,144–146]
HUVEC treated with ↑TSH Atherosclerosis ↓eNOS expression [107]
HUVEC treated with ↑T3 and ↑oxLDL Atherosclerosis ↓NO [135]
ED-endothelial dysfunction; eNOS-endothelial nitric oxide synthase; HUVEC-human umbilical vein endothelial cells; NO-nitric oxide; NOS-nitric oxide synthase;
oxLDL- oxidized low-density lipoprotein; T3-triiodothyronine; TSH-thyroid-stimulating hormone; ↑-increased; ↓-decreased.
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patients [11,73,75].
3. Nitric oxide and hypothyroidism
Hypothyroidism has two-stages based on clinical manifestations and
biochemical characteristics: a/ subclinical and b/ clinical hypothyr-
oidism [76,77]. Hypothyroidism is prevalent in 20 % of the general
population; moreover, at least 80 % of patients with hypothyroidism
are subclinically hypothyroid [78], while the prevalence of clinical
hypothyroidism is signiﬁcantly lower, less than 1 % in non-endemic and
more than 5 % in endemic areas [78–86].
Thyroid hormones have multiple roles in the normal CVS func-
tioning [87,88]. Both the myocardial and vascular endothelial tissues
present TSH receptors, so even slight alterations in TSH concentrations
can aﬀect CVS functioning [89]. Endothelial cells also express TSH
receptors, but TSH exhibits its eﬀect on endothelial cells independently
of the peripheral thyroid hormones [90,91]. Contrary, the morphology
and function of CVS are altered in subclinical and clinical hypothyr-
oidism [92], and the development of alterations depends on the severity
and duration of thyroid dysfunction [93–96]. Hypothyroidism occurs
with dyslipidemia, hypertension, blood hypercoagulability, increased
arterial wall stiﬀness, maladaptive cardiac remodeling, ED, and ele-
vated levels of C-reactive protein (CRP). All these factors lead to an
elevated risk of coronary heart disease and heart failure
[8,10,92,97–100]. Also, the level of TSH is a reliable predictor of CVD
in hypothyroid patients [101].
Alterations in CVS physiology in clinical hypothyroid patients in-
clude a reduced heart rate and cardiac contractility, as well as increased
peripheral vascular resistance [102]. In subclinical hypothyroid pa-
tients, the most frequent CVS abnormalities include increased systemic
vascular resistance and diastolic dysfunction, ED, impaired ventricular
ﬁlling and relaxation [4,95,103]. Decreased endothelium-dependent
vasodilatation in the aorta and renal blood vessels, with a concomitant
decrease in eNOS activity, was demonstrated in hypothyroid rats
[104–106]. Endothelial cells from human umbilical veins under con-
ditions of elevated TSH levels, exhibit decreased expression of eNOS
[107]. The prevalence of ED is marked up in both subclinical and
clinical hypothyroid patients, implying a role for serum TSH in ED
pathology [23].
Furthermore, the progression of hypothyroidism occurs with an
increase in CRP [23], tumor necrosis factor-α (TNF-α), and interleukin
6 (IL-6) levels [108]. The inﬂammatory markers characteristic for hy-
pothyroidism correlates with hypothyroidism etiology (chronic auto-
immune thyroiditis), as well as the pulse wave velocity, a marker of
endothelium-dependent dysfunction [109,110]. Additionally, multiple
linear regression models showed a correlation between TSH and NO
levels, after adjustment for other CVD risk factors, suggesting elevated
TSH aﬀects the progression of atherosclerosis in patients with hy-
pothyroidism [9,111]. Hyperlipidemia presented in hypothyroid pa-
tients also causes ED by decreasing eNOS expression [112]. However,
the correction of hyperlipidemia in hypothyroid patients only partially
restores endothelium-dependent vasodilatation and ED [101].
During the ﬁrst trimester of pregnancy, the mothers’ thyroid and
placenta play a pivotal role in the maintenance of thyroid hormones
supply to the fetus. The increase in activity enlarges the volume of the
thyroid gland as compared to the non-pregnancy state [113]. In such a
period, the importance of microelements and nutrients supply required
for the syntheses of thyroid hormones is cumbersome [114]. Despite
that, some mothers experience the lowering of levels of peripheral
thyroid hormones, especially thyroxine (T4). Nonetheless, even in the
cases where the mother has low T4 levels, the adaptive responses of the
placenta, changes in expression and activity of placental thyroid hor-
mone transporters and deiodinase, ensure availability of enough triio-
dothyronine (T3)/T4 that is essential for fetus growth and develop-
ment. Placental endothelial cells are under the close inﬂuence of
thyroid hormones. These hormones may induce the synthesis and
release of vasoactive mediators, such as NO and endothelin-1, and
hence control the fetoplacental circulation network. Mothers frequently
experience low levels of T4 with gestational diabetes, which could
additionally contribute to the current and delayed vascular damage, as
well as organ damage of both mother and fetus [115–117].
Latent and overt hypothyroidism induces deleterious cardiovascular
eﬀects [118,119]. Beside deranged vascular relaxation mediated by
decreased endothelial NO production, coronary arteries in hypothyroid
patients are prone to accelerated atherosclerosis [120]. Moreover, hy-
pothyroidism contributes to the aggravation of the already failed heart
muscle. After an acute myocardial injury occurs, the state of local hy-
pothyroidism, i.e., decreased T3 production/activity associated with T3
deiodinase activity, promotes early as well as late heart remodeling.
Cardiovascular dysfunctions caused by both types of hypothyroidism
could be partially or even entirely restored by LT4 replacement
[97,120,121].
4. The proposed implications of hypothyroid states on nitric oxide
production
The endothelium is a target tissue of thyroid hormones, and it is
suﬃciently sensitive to detect changes in thyroid hormones action
[9,122,123]. Both, clinical and subclinical hypothyroidism initiate CVD
through disruption of the healthy endothelial function in several ways,
by promoting inﬂammation, inducing lipid disorders and oxidative
stress, and increasing blood pressure [110,122,124,125]. All these
factors inﬂuence the expression and activity of diﬀerent vasorelaxant
and vasoconstrictor molecules, among which, those that regulate NO
production are in the most critical group [7,124]. In hypothyroid states,
the expression of hepatic low-density lipoprotein (LDL) receptors and
activity of cholesterol-α-monooxygenase decreases, leading to reduced
LDL clearance [126]. Dyslipidemia increases asymmetrical dimethy-
larginine (ADMA) levels and reduces the enzymatic activity of di-
methylarginine dimethylaminohydrolase, which leads to decreased NO
production [7,74]. Concurrently, in hypothyroid states, the in-
ﬂammatory processes also promote ED by decreasing eNOS expression
and increasing the level of endothelin-1 [7,127,128]. Although this
process is poorly understood, evidence implicates the involvement of
diﬀerent inﬂammatory factors, such as CRP, IL-6, and TNF-α
[23,122,129]. Hypothyroid states also potentiate elevation of arginase
levels in endothelial cells, thus promoting oxidative stress and addi-
tional impairment of endothelial function [130]. Pretreatment of the
myocardial infarction rat model with T3 and T4 reduces the level of
reactive oxygen species, while increases the expression of eNOS, the
total NOS activity, and NO level in the infarcted heart [131]. The
thyroid hormones directly inﬂuence the renin-angiotensin-aldosterone
system by stimulating the synthesis of hepatic renin substrates
[11,132]. In hypothyroid states, the level of renin reduces, while the
blood pressure is elevated [132].
Thyroid hormones exert their eﬀects in CVS through genomic and
non-genomic signaling pathways. These hormones aﬀect endothelium
and VSMC mostly by binding of T3 to the nuclear receptors (THR-α1
and THR-β) and regulating transcription of diﬀerent genes, including
the NOS3 gene that encodes for eNOS [11,133]. T3 also directly reg-
ulates vascular tone via non-genomic signaling that includes involve-
ment of phosphatidylinositol 3-kinases (PI3K)/Akt cascade and stimu-
lation of NO production by eNOS in endothelial cells [134–136].
Evidence suggests impaired endothelium-dependent vascular relaxa-
tion, in hypothyroid states, is caused by increases in oxidized LDL that
inhibits the non-genomic action of T3 through Akt signaling [135]. T3
also induces vasorelaxation through the endothelium-independent
pathway by stimulating the activation of PKG/vasodilator-stimulated
phosphoprotein (VASP) signaling in VSMC [137]. Thyroid hormone
stimulates L-Arg uptake to endothelial cells by upregulating L-Arg
transporters. T3 may be exerting this eﬀect through the activation of
αvβ3 integrin receptor, mitogen-activated protein kinase (MAPK),
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PI3K, and intracellular Ca2+ signaling pathways [75]. One additional
proposed mechanism of thyroid hormones action on endothelium has
been through the regulation of caveolin protein function [138], as in a
hypothyroid state, atrial NOS activity decreases, which is associated
with increased caveolin 1 expression [138]. In the subclinical hy-
pothyroid state, elevated TSH level may be responsible for the depri-
vation of eNOS, since an increased TSH bind extrathyroidal TSH re-
ceptors and decrease eNOS and prostacyclin I2 expression in
endothelial cells [90,107].
Increasing evidence underlines the critical role of NO in damage of
diﬀerent tissues during hypothyroidism [115,139–143], where the
brain tissue is the most exhaustively investigated [140,141,144–146].
Thyroid hormones are necessary for the period of early fetal neurode-
velopment [147]. Numerous experimental studies showed that hy-
pothyroidism is associated with learning and memory impairment
[148,149]. Morphological development and functional capacity of
hippocampi are under the inﬂuence of thyroid hormones [148,150].
Additionally, some results pointed out the link between NO and im-
pairment (mentioned above) [151], as well as that such hypothyr-
oidism-induced impairment inﬂuences the hippocampi, where the in-
creased expression of nNOS and elevated NO levels were detected
[152]. Such an increase in nNOS expression and NO levels is associated
with neuronal death in the rat cortex, which suggests NO also functions
as a neurogenesis inhibitor [153]. It is noteworthy that even transient
maternal hypothyroidism was associated with an increase in nNOS
expression and NO levels and was restored to pre-experimental levels
by LT4 [152,154]. The eﬀects of NO in hippocampi depend on local NO
quantity. If the production rate is physiological, NO is acting as a
neurotransmitter. In the cases of increased and extremely high pro-
duction, it exhibits inhibitory and even toxic on neurons [155]. Such
deleterious eﬀects could be explained by the link between NO and
mediators of oxidative stress [141,156]. Low levels of serum T4 lead to
a reduction of thiol content and activity of SOD and CAT enzymes, and
increased lipid peroxidation, NO metabolite levels, and neuronal
apoptosis in brain tissues of hypothyroid rats [140,141,144–146].
These ﬁndings point directly to the relationship between locally dis-
turbed NO production in hypothyroid state and brain tissue oxidative
damage, including cognitive dysfunction of experimental animals
[140,141,144–146].
Besides the eﬀects on the cardiovascular and central/peripheral
nervous system, thyroid dysfunction can cause damage to other organs
and systems as well. Pulmonary hypertension is frequently associated
with toxic multinodular goiter. A deranged balance between pulmonary
vascular dilation (decreased) and constriction (increased) is the basis of
pulmonary hypertension. In advanced stages of the disease, cardior-
espiratory failure developed [142]. Also, autoimmune disorders pre-
dominate regarding the etiology of thyroid dysfunctions. The cytokines
produced by the immune system and thyroid follicular cells favor local
and systemic inﬂammation by promoting B and T cell stimulation and
by enhancement the production of NO and various prostaglandins
[143].
5. Eﬀect of levothyroxine replacement therapy on serum nitric
oxide levels
Levothyroxine (Fig. 1), the synthetic levo isomer of T4 hormone, is
the most commonly used replacement therapy for the deﬁciency of
thyroid hormones (hypothyroidism) [157,158].
Since LT4 acts as an endogenous T4, a naturally synthesized form,
LT4 could also be converted peripherally to its active metabolite, T3.
During LT4 therapy, the serum level of T3 also increases, T3 reaches the
reference value, and by that also contributes to the decrease in the TSH
level [157,158]. Oral use of LT4 reverses symptoms and signs of hy-
pothyroidism and restores the wellbeing of hypothyroid patients with
minimal side-eﬀects such are headaches, increased appetite, and fatigue
[157].
Numerous interventional studies [95,103,120,159–163] report the
beneﬁcial eﬀects of LT4 replacement regarding the improvement of
cardiac and endothelial functions and the correction of some modiﬁable
atherosclerotic risk factors in patients with hypothyroidism. LT4 re-
placement therapy should also be introduced in subclinical hypothyroid
patients not only for the management of thyroid hormone levels but
also for preventing atherosclerosis [164]. Clinical review [165] also
reports the moderate beneﬁcial eﬀect of LT4 on numerous CVD risk
factors in patients with subclinical hypothyroidism. Moreover, LT4
treated patients exhibited signiﬁcant decreases in overall cholesterol,
Apo-B, and LDL. As TSH and lipids levels were higher before the LT4
treatment, the decrease in these parameters level was more signiﬁcant.
ED usually precedes atherosclerosis and correlates with an increase
in the level of serum lipids in hypothyroidism [166]. The critical factor
of endothelial function is the level of NO, which is directly modulated
by the thyroid hormone level [164,167]. In both types of hypothyr-
oidism, reduced NO bioavailability occurs with changes in athero-
sclerotic risk factors, that are reversible with LT4 replacement therapy
[100]. LT4-treated hypothyroid patients [72,168,169] also exhibit
normalization of the lipid proﬁle and a partial restoration of altered
endothelium-dependent vasodilation. Moreover, endothelium-depen-
dent vasodilatation is improved by LT4 replacement via restoration and
increase of NO production [72]. Also, Ozcan et al. show that an altered
level of NOS inhibitor, ADMA, and consequently altered L-Arg and NO
levels are signiﬁcantly improved in subclinical hypothyroid patients
one month after stable laboratory euthyroidism achievement by LT4
[74]. The same authors suggest that LT4, as an exogenous thyroid
hormone, is beneﬁcial for ED via lowering serum ADMA level and
elevating NO production in subclinical hypothyroidism, while the
precise molecular mechanism should be further investigated. The re-
sults reported by Hashemi et al. [164] does not corroborate the bene-
ﬁcial eﬀect of LT4 on NO levels. They conducted a case-control study on
50 female subjects (25 control and 25 case group subjects). Serum NO
levels, as well as other parameters that aﬀect the development of ED
(total cholesterol, TG, LDL, high density lipoprotein (HDL)), were
measured before and two months after LT4 replacement therapy. Re-
sults show that LT4 replacement therapy did not aﬀect the level of total
cholesterol, LDL, HDL, and the level of TG decreases after two months
of replacement therapy. Also, there was no signiﬁcant correlation be-
tween serum NO levels in the case group before and after LT4 re-
placement therapy [164]. Contrary, the beneﬁcial eﬀects of LT4 re-
placement therapy on endothelial cell functions in subclinical
hypothyroid patients are conﬁrmed in a randomized, crossover trial
[120]. One of the pieces of evidence that support a successful anti-
atherogenic and antioxidative role of LT4 substitution is the decrease in
macrophages, T lymphocytes, and proinﬂammatory HLA-DR cells count
in the plaque. CVS alterations, like systolic and diastolic dysfunction,
increased systemic vascular resistance, and decreased myocardial con-
tractility, are almost eliminated or reduced by LT4 treatment. Also,
subclinical hypothyroid patients, who had treatments switched to LT4,
show signiﬁcantly reduced risk of heart failure and overall mortality
compared to untreated patients [170,171]. Partial or complete repair of
harmful eﬀects of hypothyroidism on CVS enabled by LT4 could be
Fig. 1. Chemical structure of Levothyroxin.
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veriﬁed either as alleviation of ischemic heart disease complaints or as
improvement of ventricular rhythm disorders [84,168,172,173].
Although there are no randomized trials in patients with hy-
pothyroidism that unequivocally pointed to beneﬁcial eﬀects of LT4
treatment in the reduction of cardiovascular morbidity and mortality
rates after LT4 replacement and consequent laboratory euthyroidism
achievement, some CVS changes such as NO production [23,72] could
be at least partially restored [174]. Timely introduction of LT4 in
subclinical hypothyroid patients prevents the progression of hy-
pothyroidism and decelerates the process of atherosclerosis [72,126].
6. Conclusions
Alterations in NOS activity and NO production are involved in the
cardiovascular manifestations of thyroid disorders. LT4 replacement
reverses CVS changes related to NO bioavailability in both types of
hypothyroidism [100]. The mechanism responsible for the regulation of
NOS activity and NO bioavailability in hypothyroidism is however not
fully understood, and it may be aﬀected by various factors alone or in
combination. Future studies should focus on a better understanding of
the molecular mechanisms underlying the eﬀects of NO under physio-
logical conditions as well as in the pathophysiology of hypothyroidism
and their clinical relevance. Moreover, further investigations using
animal models and humans are needed to establish the best way to
supplement thyroid hormones and to enhance the thyroid hormones/
NO pathway. Also, more extensive clinical trials are needed to conﬁrm
the beneﬁcial eﬀects of LT4 treatment in the reduction of cardiovas-
cular morbidity and mortality rates. Regulation of NO bioavailability
after employing LT4 drugs is critical for developing new strategies for
the treatment of cardiovascular disorders associated with hypothyr-
oidism as NO could have both beneﬁcial and detrimental eﬀects. Un-
derstanding how thyroid hormones regulate NO production may pro-
vide useful knowledge about the link between thyroid diseases and ED,
and may also unveil potential new treatments for cardiovascular man-
ifestations of thyroid disorders that can prevent the onset of cardio-
vascular abnormalities in patients with hypothyroidism.
The literature discussed in this review, together with our published
data and preliminary results related to NO regulation in hypothyr-
oidism [12], suggest that NO levels could be a reliable marker for the
assessment of thyroid dysfunction and one of the critical therapeutic
molecules for improving the treatment of CVD related to thyroid dys-
function. Furthermore, the newly discovered role of thyroid hormones
and the eﬀects of LT4 on NO production may have broad implications
in cardiovascular medicine.
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